205 related articles for article (PubMed ID: 37753834)
1. Novel JAK inhibitors under investigation for systemic lupus erythematosus: - where are we now?
Nakayamada S; Tanaka Y
Expert Opin Investig Drugs; 2023; 32(10):901-908. PubMed ID: 37753834
[TBL] [Abstract][Full Text] [Related]
2. Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus.
Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2022 Mar; 18(3):245-252. PubMed ID: 35138987
[TBL] [Abstract][Full Text] [Related]
3. Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter P; Cardoneanu A; Burlui AM; Macovei LA; Bratoiu I; Buliga-Finis ON; Rezus E
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233087
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.
Ma L; Peng L; Zhao J; Bai W; Jiang N; Zhang S; Wu C; Wang L; Xu D; Leng X; Wang Q; Zhang W; Zhao Y; Tian X; Li M; Zeng X
Autoimmun Rev; 2023 Dec; 22(12):103440. PubMed ID: 37678618
[TBL] [Abstract][Full Text] [Related]
5. Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus.
Huo R; Huang X; Yang Y; Lin J
J Inflamm Res; 2023; 16():1471-1478. PubMed ID: 37051062
[TBL] [Abstract][Full Text] [Related]
6. State-of-the-art treatment of systemic lupus erythematosus.
Tanaka Y
Int J Rheum Dis; 2020 Apr; 23(4):465-471. PubMed ID: 32134201
[TBL] [Abstract][Full Text] [Related]
7. The Jakinibs in systemic lupus erythematosus: progress and prospects.
Mok CC
Expert Opin Investig Drugs; 2019 Jan; 28(1):85-92. PubMed ID: 30462559
[TBL] [Abstract][Full Text] [Related]
8. Current treatment of systemic lupus erythematosus: a clinician's perspective.
Katarzyna PB; Wiktor S; Ewa D; Piotr L
Rheumatol Int; 2023 Aug; 43(8):1395-1407. PubMed ID: 37171669
[TBL] [Abstract][Full Text] [Related]
9. Systemic lupus erythematosus.
Tanaka Y
Best Pract Res Clin Rheumatol; 2022 Dec; 36(4):101814. PubMed ID: 36702700
[TBL] [Abstract][Full Text] [Related]
10. Systemic lupus erythematosus: review of synthetic drugs.
Tsang-A-Sjoe MW; Bultink IE
Expert Opin Pharmacother; 2015; 16(18):2793-806. PubMed ID: 26479437
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic and Therapeutic Relevance of JAK/STAT Signaling in Systemic Lupus Erythematosus: Integration of Distinct Inflammatory Pathways and the Prospect of Their Inhibition with an Oral Agent.
Alunno A; Padjen I; Fanouriakis A; Boumpas DT
Cells; 2019 Aug; 8(8):. PubMed ID: 31443172
[TBL] [Abstract][Full Text] [Related]
12. [Biologics and systemic lupus erythematosous : new insights and perspectives].
Clottu A; Horisberger A; Comte D
Rev Med Suisse; 2021 Apr; 17(733):684-689. PubMed ID: 33830700
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic strategies targeting abnormal T-cell signaling in systemic lupus erythematosus.
Mizui M; Kono M
Clin Immunol; 2024 May; 262():110182. PubMed ID: 38458302
[TBL] [Abstract][Full Text] [Related]
14. JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.
Ikeda K; Hayakawa K; Fujishiro M; Kawasaki M; Hirai T; Tsushima H; Miyashita T; Suzuki S; Morimoto S; Tamura N; Takamori K; Ogawa H; Sekigawa I
BMC Immunol; 2017 Aug; 18(1):41. PubMed ID: 28830352
[TBL] [Abstract][Full Text] [Related]
15. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
16. JAK inhibitors and autoimmune rheumatic diseases.
Benucci M; Bernardini P; Coccia C; De Luca R; Levani J; Economou A; Damiani A; Russo E; Amedei A; Guiducci S; Bartoloni E; Manfredi M; Grossi V; Infantino M; Perricone C
Autoimmun Rev; 2023 Apr; 22(4):103276. PubMed ID: 36649877
[TBL] [Abstract][Full Text] [Related]
17. Baricitinib for the treatment of rheumatoid arthritis and systemic lupus erythematosus: a 2019 update.
Kubo S; Nakayamada S; Tanaka Y
Expert Rev Clin Immunol; 2019 Jul; 15(7):693-700. PubMed ID: 30987474
[No Abstract] [Full Text] [Related]
18. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
Steiger S; Ehreiser L; Anders J; Anders HJ
Front Immunol; 2022; 13():999704. PubMed ID: 36211360
[TBL] [Abstract][Full Text] [Related]
19. Autoimmune Responses and Therapeutic Interventions for Systemic Lupus Erythematosus: A Comprehensive Review.
Pandey SP; Bhaskar R; Han SS; Narayanan KB
Endocr Metab Immune Disord Drug Targets; 2024; 24(5):499-518. PubMed ID: 37718519
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
